Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Alzheimer's Disease Meta-Analysis Identifies New Risk Genes

By LabMedica International staff writers
Posted on 11 Mar 2019
The risk for late-onset Alzheimer’s disease (LOAD), the most prevalent dementia, is partially driven by genetics. More...
Scientists have uncovered five new late-onset Alzheimer's disease risk genes in a genetic meta-analysis. They likewise confirmed 20 other genes previously linked to late-onset Alzheimer's risk.

A very large team of scientists led by those at the University of Miami Miller School of Medicine (Miami, FL, USA) combined 46 different datasets to yield an overall set of 35,274 clinical and autopsy-documented Alzheimer's cases and 59,163 controls to interrogate. Through the first two stages of their multi-stage analysis, they uncovered 21 loci reaching genome-wide significance, 18 of which had previously been identified. After the third stage of their investigation and an overall meta-analysis, they identified 13 novel loci associated with risk of late-onset Alzheimer's.

They identified the genes through a genome-wide association meta-analysis using data from more than 94,000 people, which also enabled them to tie certain biological processes like immune response, lipid metabolism, tau binding proteins, and amyloid precursor protein metabolism to disease. This, they noted, suggests that variants affecting amyloid precursor protein (APP) and beta amyloid (Aβ) processing play roles in both early- and late-onset Alzheimer's. Amyloid plaques of Aβ protein and neurofibrillary tangles of tau protein are disease hallmarks.

The team combined together various line of evidence, such as gene annotation, expression quantitative trait loci (eQTL) analyses, gene expression analysis, and pathway analyses, they prioritized candidate genes at the novel signals they found, implicating the IQCK, ACE, ADAM10, ADAMTS1, and WWOX genes in Alzheimer's risk. ADAM10, for instance, encodes an alpha secretase that is active in the brain and is part of the non-amyloidogenic pathway of APP. WWOZ, which is a high-density-lipoprotein cholesterol and triglyceride-associated gene, is highly expressed in astrocytes and neurons, and binds tau, where it may regulate tau hyper-phosphorylation, the formation of neurofibrillaries, and aggregation of Aβ.

The team noted that pathway analysis showing that tau is involved in late-onset Alzheimer's supports recent evidence that tau may play an early pathological role in the disease and confirms that therapies targeting tangle formation or degradation could potentially affect late-onset disease. Their analysis of risk genes and disease-linked pathways also indicated an enrichment of rare variants in late-onset Alzheimer's disease risk and suggested there might be additional rare variants to find if larger samples are studied. The study was published on February 28, 2019, in the journal Nature Genetics.

Related Links:
University of Miami Miller School of Medicine


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Candida Glabrata Test
ELIchrom Glabrata
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.